Germline genetic testing examines cancer predispositions and enables early treatment. Every fifth tumor develops due to a hereditary predisposition. Prevention is the most important measure in the fight against tumor diseases. Knowing predispositions and initiating appropriate early-detection examinations are central components in preventing metastatic and late-detected disease progression. Genetic tumor diagnosis is especially important for persons with a family history of cancer as it assesses their risk of developing cancer.
The Diagnostic Panel for Hereditary Tumor Diseases is based on exome sequencing with CeGaT’s ExomeXtra®. CeGaT’s ExomeXtra® covers all protein-coding regions as well as all known pathogenic intronic and intergenic variants. It thus provides the best basis for genetic diagnostics.
Are you insured in Germany? Our colleagues at the Zentrum für Humangenetik Tübingen will gladly support you!
What We Offer with the Panel for Hereditary Tumor Syndromes
Our Promise to You
Your Benefits
It is possible to request single or multiple predefined gene sets. In addition to the complete analysis of the genes of the requested gene set, we extend the analysis by additional genes for differential diagnosis. We report variants of unknown significance (ACMG class 3) and pathogenic and probably pathogenic variants (ACMG classes 4 and 5) for the primarily ordered gene set. For the genes included due to differential diagnosis, we restrict the reporting to pathogenic and probably pathogenic variants (ACMG classes 4 and 5), which could be related to the indication of the person seeking advice.
The Diagnostic Panel for Hereditary Tumor Syndromes is based on CeGaT’s ExomeXtra® enrichment. This allows, without additional sequencing, phenotypically eligible gene sets of other CeGaT panels or single genes to be additionally ordered. If you would like to assemble an individual panel, please feel free to contact us. We will be happy to support you.
In addition to the primary diagnostic assignment, the assessment of ACMG genes and pharmacogenetic profiling may also be ordered.
Method
The enrichment of the coding regions and the adjacent intronic regions is performed using an in-solution hybridization technology. The selection of the targeted regions and the design of the enrichment baits is performed in-house. High-throughput sequencing is performed on our Illumina platforms. Bioinformatic processing of the data is achieved using an in-house computer cluster.
Following data processing, our team of scientists and specialists in human genetics analyze the data and issue a medical report.
Sample Report
General Information
Material
- 1–2 ml EDTA blood (recommended sample type) or
- 1–2 µg genomic DNA
- Order Form with declaration of consent
Here you can find more information on how to ship your sample safely.
Costs
The prices for our human genetic diagnostics depend on the size of the selected diagnostic panel and the selected gene sets. All prices include sequencing, bioinformatic analysis, and issuing of a medical report by our team of experts in human genetic diagnostics.
Colorectal Cancer
Colorectal Cancer (CAN01, 26 Genes)
APC, ATM, AXIN2, BMPR1A, BRIP1, CDH1, CHEK2, GREM1, MBD4, MLH1, MSH2 (inkl. relevanter Elemente im 3‘-Bereich von EPCAM), MSH3, MSH6, MUTYH, NF1, NTHL1, PMS2, POLD1, POLE, PTEN, RNF43, RPS20, SCG5, SMAD4, STK11, TP53
Optional MLPA Set
MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PMS2
Gynecologic Cancer – Extended Diagnostics (Optional After/ Together with CAN02; Including Candidate Genes) (CAN21, 25 Genes)
No detection of a pathogenic or likely pathogenic variant in 15 core genes.
ABRAXAS1, BAP1, BLM, CDC73, DICER1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MRE11, MUTYH, NBN, POLE, RAD50, RECQL4, RINT1, SLX4, SMARCA4, TGFBR1
Gastrointestinal Neoplasia
Gastric Cancer (CAN13, 15 Genes)
APC, ATM, BRCA2, CDH1, CHEK2, CTNNA1, KIT, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PDGFRA, PMS2, SMAD4, SKT11, TP53
Optional MLPA Set
BRCA2, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PMS2
Pancreatic Cancer
Pancreatic Cancer (CAN06, 13 Genes)
APC, ATM, BRCA1, BRCA2, CDKN2A, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PALB2, PMS2, STK11, TP53, VHL
Optional MLPA Set
BRCA1, BRCA2, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PMS2
Tumors of the Central Nervous System
Tumors of the Central Nervous System (CAN51, 22 Genes)
APC, DICER1, ELP1, LZTR1, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, MUTYH, NF1, NF2, PMS2, POT1, PTCH1, PTEN, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL
Optional MLPA Set
MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PMS2
Urological Tumors
Prostate Cancer (CAN03, 13 Genes)
ATM, BRCA1, BRCA2, CHEK2, HOXB13, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, NBN, PALB2, PMS2, RAD51D, TP53
Optional MLPA Set
BRCA1, BRCA2, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PMS2
Renal Cell Cancer (CAN07, 24 Genes)
BAP1, CDC73, CDKN1C, CHEK2, DICER1, FH, FLCN, GPC3, MET, MITF, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL, WT1
Optional MLPA Set
MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PMS2
Solid Pediatric Tumors
Solid Pediatric Tumors (CAN22, 36 Genes)
ALK, APC, BLM, BRCA2, CTR9, DICER1, DIS3L2, GPC3, HRAS, MEN1, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, NBN, NF1, NF2, PALB2, PHOX2B, PMS2, PRKAR1A, PTCH1, PTEN, RB1, RECQL4, REST, RET, SMARCA4, SMARCB1, STK11, SUFU, TP53, TRIM28, TSC1, TSC2, VHL, WT1
Optional MLPA Set
BRCA2, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PMS2
Other Familial Tumor Diseases
Other Familial Tumor Diseases (CAN05, 32 Genes)
AKT1, ATR, BAP1, BLM, BRCA1, BRCA2, CDC73, CHEK2, CYLD, FH, FLCN, LZTR1, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, NF1, NF2, PIK3CA, PMS2, PTEN, SDHB, SDHC, SDHD, SEC23B, SMARCB1, SPRED1, STK11, TP53, TSC1, TSC2, VHL, WRN
Optional MLPA Set
BRCA1, BRCA2, MLH1, MSH2 (incl. epigenetically relevant elements in the 3‘ region of EPCAM), MSH6, PMS2
For Xeroderma Pigmentosum (formerly CAN08) and Fanconi anemia (formerly CAN10) please refer to order forms skin diseases (DRM10) and blood disorders (BLD05).
Gene Directory – Panel for Hereditary Tumor Syndromes
ABRAXAS1, ACD, AIP, AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, CDKN2C, CHEK2, CTNNA1, CTR9, CYLD, DICER1, DIS3L2, DLST, EGFR, EGLN1, ELP1, EPCAM, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GPC3, GREM1, HOXB13, HRAS, KIF1B, KIT, LZTR1, MAX, MBD4, MDH2, MEN1, MET, MITF, MLH1, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTCH2, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, REST, RET, RINT1, RNF43, RPS20, SCG5, SDHA, SDHAF2, SDHB, SDHC, SDHD, SEC23B, SLX4, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPRED1, STK11, SUFU, TERF2IP, TERT, TGFBR1, TMEM127, TP53, TRIM28, TSC1, TSC2, VHL, WRN, WT1
Additional Services
HLA-Typing (HLA01)
HLA class I (Gene A, B, C) and HLA class II (Gene DPA1, DPB1, DQA1, DQB1, DRB1, DRB3, DRB4, DRB5)
ACMG Genes
Genetic variation may sometimes be identified, which does not fit within the scope of the requested genetic analysis (so-called secondary findings). The reporting of these variants is limited to pathogenic alterations (ACMG classes 4 and 5) within selected genes, for which a treatment or course of action exists for you or your family (according to the current guidelines of the American College of Medical Genetics and Genomics).
Pharmacogenetics
Pharmacogenetic analysis detects genetic changes that affect the effectiveness of drugs. Genetic variants that affect proteins responsible for the metabolism of substances can significantly change their tolerance and efficacy. These drugs include, among others, antidepressants, pain relievers, neuroleptics, chemotherapeutics, AIDS drugs, thrombosis drugs, anesthetics, beta-blockers, or statins.
The reduced activity of a specific enzyme can lead to an increased drug level in the standard dosage, which is often associated with undesirable side effects. With drugs that are only activated by metabolism, the therapeutic effect can be completely absent. Likewise, due to the resulting increased rate of degradation of the medicinal substance, an increased enzyme activity leads to inadequate effectiveness of the therapy.
The pharmacogenetics option analyzes known variants in twenty-one genes involved in the metabolism of drugs. If specific gene variants occur, the treating doctor can adapt the therapy individually. The pharmacogenetic analysis can minimize serious side effects and helps to avoid failure of the treatment.
Contact Us
Do you have a question, or are you interested in our service?
Diagnostic Support
We will assist you in selecting the diagnostic strategy – for each patient.
